Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
55 hedge funds and large institutions have $36.8M invested in Kezar Life Sciences in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 8 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
19% more capital invested
Capital invested by funds: $30.9M → $36.8M (+$5.87M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 54 → 55 (+1)
0.13% less ownership
Funds ownership: 4.92% → 4.79% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$985K |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$985K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$359K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
+$275K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$211K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.04M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
-$1.16M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$161K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$139K |
| 5 |
AIM
Alambic Investment Management
Belvedere,
California
|
-$113K |
KZR Hedge Fund Activity: Q4 2019 in Review
55 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2019, worth a combined $36.8M — up 19% from $30.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KZR positions and 8 closed out — a net gain of 1 holder — while 22 added to existing stakes and 15 trimmed.
The largest buyer was Bellevue Group, adding an estimated $985K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.04M sold.
- 55 institutional investors held Kezar Life Sciences (KZR) as of Q4 2019, up from 54 in Q3 2019.
- Funds reported $36.8M of Kezar Life Sciences stock for Q4 2019, up 19% quarter-over-quarter.
- 9 funds opened new Kezar Life Sciences positions in Q4 2019 and 8 closed out, a net change of +1 holder.
- The largest Kezar Life Sciences buyer in Q4 2019 was Bellevue Group, an estimated $985K added.
- The largest Kezar Life Sciences seller in Q4 2019 was Cormorant Asset Management, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2019.